antibiotic-susceptible bacteria 40-word summary: In this international study we demonstrate that increasing rates of nosocomial bloodstream infections caused by antibiotic-resistant bacteria do not replace 3 infections caused by antibiotic-susceptible bacteria, but come on top of these infections, thereby increasing the total burden of disease.
INTRODUCTION

Rates of nosocomial bloodstream infections [BSI] caused by antibiotic-resistant bacteria
[ARB] are increasing worldwide. 1 Yet, associated changes in total burden of disease and the dynamical interaction between ARB and antibiotic-susceptible bacteria [ASB] have not been quantified accurately. 2 For instance, one could hypothesize that the frequent use of antibiotics in hospitalised patients creates an ecological niche for ARB that replace ASB, without increasing the total burden of disease. Alternatively, ARB and ASB may not compete, and, thus, increasing infection rates caused by ARB incur an additive burden. Such information is critical for quantifying the health-economic effects of antimicrobial resistance and demonstrating the benefits of infection control. 3 Most longitudinal studies on the epidemiology of ARB addressed a single pathogen, frequently with comparison to its antibiotic-susceptible variant, but failed to include all other pathogens. 2 To assess whether incidences remain stable or increase, one should adjust for changes in duration of hospital stay over time. Hence, incidence density (i.e., incidence rate; number of events per number of patient-days) will quantify the problem of antimicrobial resistance more accurately than crude numbers of events. 4 We quantified temporal trends in the microbiologic aetiology of nosocomial BSI due to ARB and ASB in 14 hospitals in Europe, North and South America over a 10-year period. We categorized hospitals as those with and without endemic ARB. We aimed to determine if ARB replace ASB, or if (and to what extent) they are additive to the total burden of nosocomial BSIs.
METHODS
Ethics statement
Institutional review boards in most of the participating hospitals did not require a formal protocol review because this study was retrospective, thus, did not affect patient care, and data were deidentified. Oxford data came from the Infection in Oxfordshire Research
Database, approved by the Oxford Research Ethics Committee (09/H0606/85) and the UK National Information Governance Board (5-07(a)/2009).
Study design, study setting and study population
We performed a cohort study of patients with microbiologically confirmed nosocomial BSI by linking deidentified databases from the hospital information systems and the microbiology laboratories of the participating hospitals. Hospitals were eligible if they could provide (1) data on positive blood cultures, including susceptibility profiles, for at least seven consecutive years, (2) numbers of hospital admissions and lengths of stay for the same period, and (3) the hospital day during which blood cultures were obtained. Patients admitted to ambulatory care and psychiatric units were excluded. Species identification and susceptibility testing were performed according to local guidelines and procedures.
We initially used the 2005 figures of MRSA reported by existing surveillance programs to categorize hospitals based on their countries proportion of MRSA among S. aureus invasive infections, being more or less than 0.10, as having high or low infection rates of ARB.
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After data collection we quantified the proportion of MRSA and ARB isolates and the incidence densities of nosocomial MRSA BSI and ARB BSI in 2005.
Data collection and variables of interest
The hospitals' microbiological databases were linked to patient-administrative systems, thereby providing a database with all patient admissions. The database included microbiological results of all positive blood cultures obtained, and data on gender, age, department of admission, and length of stay before nosocomial BSI acquisition. Hospital departments were categorized as surgery, medicine, and mixed departments and patient care units were categorized as intensive care units or regular wards.
Definitions
Bloodstream infection: Isolation of bacteria or fungi from at least one blood culture set.
Microorganisms typically considered to be skin flora (coagulase-negative staphylococci,
Micrococcus species, Bacillus species, diphteroids (corynebacteria or propionibacteria) were considered to be probable contaminants and were excluded.
Nosocomial BSI: BSI occurring more than 48 hours after hospital admission and in patients who did not have documented BSI with the same microorganism during the first 48 hours after admission.
Polymicrobial BSI: BSI with more than one microorganism in a single set of blood cultures or in different blood culture sets obtained within 48 hours of the first positive blood culture. Figure 1) . In a second sensitivity analysis, we excluded hospitals with the most extreme nosocomial BSI incidence densities (Porto Alegre and Utrecht for the ARB-endemic and ARB-non-endemic hospitals, respectively).
We assessed changes in the incidence densities of nosocomial BSI to describe changes in the overall burden of disease over time, and we assessed changes in the incidence densities of cultured microorganisms (including each microorganism in polymicrobial nosocomial BSI)
to describe changes in burden of nosocomial BSI infections caused by MRSA, ARB, and ASB. Incidence densities were calculated as the number of events per 100 000 patient-days.
We modelled temporal trends of incidence densities using Poisson regression, presenting yearly change in incidence density as a rate ratio [RR] with a 95% confidence interval. To determine whether differences between RRs from ARB-endemic and ARB-non-endemic hospitals were statistically significant, we calculated the p-value for heterogeneity.
We repeated calculations with number of events per 10 000 admissions (cumulative incidence), to allow for the possibility of non-parametric changes in length of stay after the onset of nosocomial BSI compared to overall length of stay over the study period, leading to an overestimation of increased burden of disease when expressed as incidence densities (Supplementary Table 2 ).
We used  2 tests for dichotomous variables, univariable logistic regression for categorical variables, and Mann Whitney U tests for continuous, non-normally distributed variables to analyze relations between patients and ARB endemicity. The data were analyzed using SPSS version 15.0 (SPSS, Chicago, Ill., USA) and R version 2.6.0. .000 patient-days among hospitals in countries with low MRSA rates (ARB-non-endemic hospitals) and from 9.9 to 91/100.000 patient-days among hospitals in countries with high MRSA rates (ARB-endemic hospitals), which implies that the proportion of MRSA -in these hospitals-is a reliable proxy for ARB BSI.
RESULTS
Hospital characteristics
During the study period, 4.992.357 patients were admitted for a total of 36.391.175 patientdays. The annual number of patient-days increased by 0.3% among ARB-non-endemic hospitals and increased by 0.5% among ARB-endemic hospitals (Supplementary Table 3 ).
Microbiology
Over the study period, 202.523 positive blood cultures were obtained (not including probable contaminants) during 64.417 BSI episodes (Figure 1 
Patient characteristics
Incidence rates of nosocomial BSI
Between 1998 and 2007, the average incidence density of nosocomial BSI per hospital ranged from 62.3 to 185.5/100.000 patient-days. The 10-years trend of annual incidence densities increased in twelve hospitals, decreased by 1% in one hospital, and did not change significantly in another one. The increase in incidence densities was mainly due to increased rates of Enterococcus spp., anaerobes, and Candida spp. in ARB-non-endemic hospitals and to Enterococcus spp., Enterobacteriaceae, Acinetobacter spp., and Candida spp. in ARBendemic hospitals ( Table 1 ). The incidence density trends for nosocomial BSI caused by ASB, MRSA, and non-MRSA ARB, in the participating hospitals are shown in Figure 2 .
From 1998 to 2007, the incidence density of nosocomial BSI caused by MRSA increased from 0.2 to 0.7/100.000 patient-days in ARB-non-endemic hospitals, an annual increase of 22% (95% CI, 6-40%). During the same period, the incidence density of MRSA increased from 3.1 to 11.7/100.000 patient-days in ARB-endemic hospitals, corresponding to an annual increase of 10% (95% CI, 9-12%; Table 2 ). While the relative rates of increase did not differ significantly between ARB-non-endemic and ARB-endemic hospitals (p=0.2), the MRSA incidence density-difference increased from 2.9 in 1998 to 11.0/100.000 patient-days in 2007. The incidence density of nosocomial BSI caused by non-MRSA ARB increased from 2.8 to 4.1/100.000 patient-days in ARB-non-endemic hospitals, corresponding to an annual increase of 5% (95% CI, 1-9%). In the same period, the incidence density of nosocomial BSI caused by non-MRSA ARB increased from 1.5 to 17.4/100.000 patient-days in ARB-endemic hospitals, an annual increase of 22% (95% CI, 20-25%) (p<0.001; Table 2 ; Supplementary   Figure 2) . As a result, the incidence density-difference between ARB-endemic and ARB-nonendemic hospitals for nosocomial BSI caused by non-MRSA ARB increased from -1.3 in 1998 to 13.3/100.000 patient days in 2007.
Trends in incidence densities of nosocomial ASB BSI were similar, with annual increases of 4.5% (95% CI, 4-5%) and 4.2% (95% CI, 4-5%) in ARB-non-endemic and ARB-endemic hospitals, respectively (p=0.7). The overall incidence density-difference between ARBendemic and ARB-non-endemic hospitals increased from 3. Sensitivity analyses evaluating data from 2000 to 2005 and evaluating data that excluded data from the hospitals with the highest rates yielded similar results (data not shown).
Moreover, trends in cumulative incidences were comparable to trends in incidence densities (Supplementary Table 2 ).
DISCUSSION
Based on detailed longitudinal data from 14 hospitals in three continents we have demonstrated that an increasing incidence of nosocomial BSI caused by ARB adds to the total burden of disease without replacing BSI caused by more susceptible bacteria. While the total burden of nosocomial BSI in both cohorts was similar in 1998, the excess increase in incidence rates of nosocomial BSI in ARB-endemic hospitals was 20.6/100.000 patient days in 2007 and almost fully attributable to increased rates of infections caused by ARB.
To the best of our knowledge, this study is the first to conduct integrated trend analyses of all relevant nosocomial pathogens on such a large multicentre dataset. This dataset allowed us to quantify the overall burden of nosocomial BSI caused by ARB and ASB. Although longitudinal changes in incidences and proportions of pathogens causing nosocomial infections have been reported previously, in most studies reported changes in the burden of disease due to ARB reflected the epidemiology of a single pathogen. 2, 9 By comparing longitudinal data from hospitals with high and lower rates of nosocomial ARB BSI, we took advantage of a natural experiment that allowed us to observe long-term effects of successful and less successful control of nosocomial spread of ARB. On a global level, this information is critical for assessing benefits of infection prevention and control strategies. In the past years, guidelines have focused specifically on prevention of ARB transmission in hospitals, in particular MRSA. [10] [11] [12] [13] Our results stress the importance of successful prevention of all ARB.
Although our study was observational, we feel that the more pronounced increase of BSIs in the ARB-endemic hospitals reflects either differences in infection prevention practices or antibiotic prescription patterns, or both, of the hospitals and their home countries. 14,15 Our findings suggest that hospitals (and their home countries) which effectively prevented emergence of MRSA were also more successful in controlling the more recent emergence of resistance among Gram-negatives.
There are three alternative explanations of our findings that need to be addressed. The first one is an imbalanced change in patient case-mix that may have occurred during the study period. Such a change in case-mix was not discernible from observed changes in age and length of stay. Moreover, annual changes in incidence rates of ASB BSI were similar in both hospital groups. The second alternative explanation would be that ARB may be more virulent than their susceptible counterparts, but this would contradict the widely accepted view that resistance is associated with reduced fitness, and published studies do not convincingly prove that antimicrobial resistance confers increased virulence on pathogenic bacteria. 16 Finally, non-parametric changes in length of stay after nosocomial BSI compared with overall length of stay could have caused us to overestimate the burden of disease when expressed as incidence density. However, the cumulative incidence, which is less sensitive to changes in the number of patient-days over time, revealed similar trends.
Our study has several potential limitations. Hospitals were included if they had the availability of an appropriate database, which could have selected hospitals with better surveillance systems and infection control policies. Naturally, results of the various participating hospitals were heterogeneous, which reflects differences in patient populations, local infection prevention measures, hospital organisation, and antibiotic prescribing practices.
Nevertheless, Figure 2 demonstrates broadly similar results across our set of hospitals, and does not suggest important ecological biases.
In addition, incidence density analysis in general might be obscured when potential competing events (e.g., in-hospital death and hospital discharge) are not taken into account. 17 However, the incidence density of nosocomial BSIs, as determined in our study, was conditional on patients being alive and hospitalized. Thus, the analysis of incidence densities corresponds to an analysis of the hazard for nosocomial BSI before in-hospital death or hospital discharge.
In theory, hospitals that obtained more blood cultures than others might have higher rates of nosocomial BSI. Since information on negative blood cultures was not part of this study, changes in blood culture practices over time could not be determined.. However, we are unaware of such changes in the participating hospitals. Moreover, we think it is unlikely that such changes differed between hospitals with high and lower rates of nosocomial ARB BSI.
Misclassification may have occurred for some positive blood cultures in patients who were discharged and then readmitted soon thereafter with a BSI, erroneously classified as community-acquired. Furthermore, we may have misclassified some nosocomial BSIs as non-infectious by excluding cultures that grew possible skin contaminants. Although some might have represented true episodes of nosocomial infection, we were unable to identify them as information of clinical signs and symptoms was lacking. 18 However, misclassification would have affected rates of nosocomial BSI in a non-differential manner.
In conclusion, we demonstrated that nosocomial BSI caused by ARB do not replace infections caused by more susceptible bacteria, but rather these infections increase the total burden of disease. This implies that successful control of antibiotic resistance improves patient outcome not only because of lower mortality from better treatable infections, but also because of a reduction, or at least a lower increase, in number of infections.
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Microorganisms non S. aureus
Non MRSA-ARB -Enterococcus spp.
Enterobacteriaceae -Acinetobacter spp.
-
P. aeruginosa
Non MSSA-ASB -Enterococcus spp.
Enterobacteriaceae -Acinetobacter spp. antibacterial agent from one of the groups in this category is sufficient to define the microorganism as highly resistant; B: resistance to antibacterial agents from at least two of the groups in this category is required to define the microorganism as highly resistant; C:
resistance to antibacterial agents from at least three of the groups in this category is required to define the microorganism as highly resistant. 1 Modified according to KluytmansVandenBergh. 8 2 Among Enterobacteriaceae, in-vitro resistance to 3 rd generation cephalosporins is a proxy measure for production of extended-spectrum beta-lactamases
[ESBL]. 3 Not applicable for Escherichia coli and Klebsiella spp.
Supplementary Table 2 
